**Abstract**

Long-term diabetes is associated with accelerated ageing of the brain as evidenced by impairment of cognitive function and motor performance as well as degenerative changes in the hippocampus. A neuroprotective role for erythropoietin (EPO) has been reported in some CNS injuries like stroke and spinal cord injury. The aim of this study was to examine the effects of erythropoietin on the induced cognitive deficits in STZ-induced diabetes mellitus. Twelve male BALB/c mice aged 5--7 weeks (20-25g) were administered streptozotocin i.p. (STZ; Sigma-Aldrich) 55mg/kg/day for 5 days. Diabetic mice were randomly assigned to either control (i.e. sodium citrate buffer i.p.) (n=6), or EPO treatment (Sigma-Aldrich) 5U/g/day (dissolved in sodium citrate buffer; i.p.) (n=6), three times per week beginning six weeks after the induction of diabetes. An additional group of six mice served as normal controls. Water maze performance by measuring the latency to reach the platform was significantly higher in the Diabetic group (92.2 ± 5 s) compared to the DM+EPO (74.8 ± 9.6 s) and control group (42.5 ± 5.4 s, ANOVA p\< 0.05) After water maze testing, the mice were decapitated and the brains removed and processed for light microscopic evaluation of dentate region of the hippocampus. In the diabetic mice, there were degenerative changes in the dentate region of the hippocampus, in the form of cell loss and shrinkage and darkening of the nuclei of other cells compared to normal mice. In contrast, there was improvement in the neurogenesis and also in the nuclear shape of the cells of the dentate region in EPO-treated diabetic mice. Conclusion: Diabetes resulted in deterioration in the cognitive power of the brain and histological degenerative changes in the dentate region of the hippocampus. These changes were ameliorated by the administration of EPO which may be useful in the treatment of diabetic neuropathy.
